Merck expands Singapore biosafety testing laboratory to over 1 000 square metres
Merck has expanded its Singapore BioReliance laboratory to over 1 000 square metres adding cell line characterisation and GMP next generation sequencing capabilities for regional biopharma clients
Merck, a global science and technology company, has announced plans to expand its Singapore lab's testing facility to over 1,000 square meters. This expansion aims to enhance biosafety and analytical testing services for customers in the Asia Pacific region, a key hub for the biopharma industry.
The company's investment underscores its commitment to supporting medicine makers with advanced analytical and biosafety testing services. The expanded facility will offer Cell Line Characterization services, GMP next-generation sequencing (NGS) capabilities, and advanced molecular methods like Blazar® for rapid virus detection.
Merck's move aligns with the industry's push towards state-of-the-art quality control testing of biologics and the 3Rs principle (Replacement, Reduction, and Refinement of animal use) through advanced molecular methods. The Singapore laboratory, opened in 2018, will become the first BioReliance® facility in the Asia-Pacific region to offer these advanced services.
Goh Wan Yee, Senior Vice President and Head of Healthcare at Singapore Economic Development Board, expressed excitement about Merck's expansion and its potential to strengthen Singapore's life science ecosystem. The Singapore BioReliance® lab, the company's first in Asia-Pacific, will now provide a comprehensive portfolio of testing services to support the region's growing biopharma industry.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
